Patent Rights and Their Impact on Pharmaceutical Markets

Introduction The recent decision of the National Company Law Appellate Tribunal (NCLAT) in “Swapan Dey v Competition Commission of India & Anr.[1]” brings back the focus on the interplay between patent rights, competition law, and public health in the pharmaceutical sector. While the case has largely been viewed as a jurisdictional determination concerning the respective […]

Global Drug Pricing Reforms and Their Commercial Fallout: A Legal Perspective On MFN and India-U.S. Pharma Trade

The U.S government revived the “Most Favoured Nation” i.e the MFN drug pricing policy in May 2025, aimed at curbing exorbitant medicine costs by tying U.S. drug prices to the lowest rates paid by developed nations. The move not only has rooted in trade law principles but has also sent ripples through the pharmaceutical world- […]